News und Analysen
Can Pfizer's Stock Break This Disappointing Streak?
Pfizer (NYSE: PFE) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.
It has developed many medicines over the years
4 Reasons to Buy Amgen Stock Right Now
Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (NASDAQ: AMGN) started the year
St Louis Financial Loads Up on AbbVie (ABBV) With 14,600 Shares Buy
St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie (NYSE:ABBV), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.
According to a Securities and
1 Reason to Buy UnitedHealth Group Stock Before Oct. 28
Health insurer UnitedHealth Group (NYSE: UNH) reports its third-quarter earnings results later this month, on Oct. 28. It could be a pivotal report for the company, which indicates whether the
Why Shares of Eli Lilly Soared This Week
Shares in Eli Lilly (NYSE: LLY) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical
Pfizer Just Made a Landmark Drug Pricing Agreement with President Donald Trump. Is the Stock a Buy?
The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald
Zoetis: A Solid Investment in the Growing Pet Medicine Market?
Explore the exciting world of Zoetis (NYSE: ZTS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends
AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?
Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early
3 Things You Need to Know if You Buy Pfizer Today
The big draw for most investors with Pfizer (NYSE: PFE) today is likely to be its lofty 7.2% dividend yield. That compares to 1.2% for the S&P 500 index and about 1.3% for the average pharmaceutical
This Medical Device Giant Could Be Your Best Inflation Hedge
Some investors fear that President Donald Trump's aggressive tariffs will lead to economic troubles such as inflation. While things may or may not turn out that way, it's still a good idea to
Why AbbVie Stock Cruised to an Almost 6% Gain Today
The announcement of a new buildout, as well as developments on the political front, were the factors driving up AbbVie (NYSE: ABBV) stock on Wednesday. The pharmaceutical company's shares rose by
Why BioNTech Stock Jumped by Nearly 4% on Wednesday
Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer
Why Pfizer Stock Trounced the Market Today
Still basking in the glow of a likely advantageous deal it signed with the government the previous day, Pfizer's (NYSE: PFE) stock was extremely healthy on Hump Day. That positive sentiment was
Why Shares in Novo Nordisk Bumped Higher Today
Shares in Novo Nordisk (NYSE: NVO) were up 6% by 11:30 a.m. on Wednesday. The move comes after Pfizer's agreement with the Trump administration raised hopes that other pharmaceutical companies
Pfizer Just Announced a Massive Deal with TrumpRx. Here's What Investors Need to Know
Pfizer (NYSE: PFE) announced on Tuesday that it had signed an agreement with the White House that will help Americans pay lower prices for prescription drugs and bolster U.S. leadership in
Better AI Dividend Stock: Apple vs. Broadcom
If you were trying to find dividend stocks before the year 2000, the largest companies in the U.S. were a great place to look. Stalwarts like General Electric (today called GE Aerospace), Pfizer
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Stocks in the S&P 500 (SNPINDEX: ^GSPC) offer a miserly yield of 1.2% (on average) today. You can do way better than that and still invest in very attractive businesses. To prove that out, just look
Stock Market Today: Pfizer Rallies on Trump Drug Pricing Deal and U.S. Investment Pledge
Pfizer Inc (NYSE: PFE) closed at $25.48, rising 6.83%. Volume soared to over 153 million shares, nearly 3.5 times its three-month average of 43.3 million.
Indexes advanced modestly, led by
Why Pfizer Stock Just Popped
Pfizer (NYSE: PFE) stock was trading 3.6% higher as of 12:01 p.m. ET Tuesday after The Washington Post reported that the Trump administration had struck a deal with the pharmaceutical giant under
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
Pfizer (NYSE: PFE)'s stock just can't seem to get out of a tailspin. It faces question marks about its future growth, and investors have effectively given up on it. Even though it looks like cheap
1 Reason This Healthcare Stock's Turnaround Is on the Horizon
It can be tough to invest in healthcare stocks. They're at the mercy of government programs that set reimbursement rates, they face political pressure on drug pricing and premiums, and they get
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Investors seeking passive income sources that grow steadily have a few interesting options to choose from right now. Shares of Brookfield Infrastructure Corp. (NYSE: BIPC), Realty Income (NYSE: O)
Why Pfizer's Post-COVID Future Looks Brighter Than Ever
It's been a rough few years to be a Pfizer (NYSE: PFE) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer (NYSE: PFE) has a huge 7.1% dividend yield. That certainly compares favorably to the broader market's 1.2% yield and the average healthcare stock's yield of 1.7%. But Pfizer's lofty yield
5 Top Stocks to Buy in October
As we enter the final three months of 2025, some investors may be looking for red-hot growth stocks with room to run. Whereas others may be searching for beaten-down stocks at compelling valuations


